ArticleMicrobial biotechnology2022
Physiological activity of E. coli engineered to produce butyric acid.
Article in Microbial biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- The Role of Genetically Engineered Probiotics for Treatment of Inflammatory Bowel Disease: A Systematic Review.Nutrients · 2023Pooled it
- Effects of protease-hydrolyzed cottonseed protein on growth performance, intestinal morphology, and bacterial diversity in broilers.Poultry science · 2026Article
- Gut microbiota-derived short-chain fatty acids in gallstones: mechanisms and intervention strategies.Frontiers in microbiology · 2026Review
- Application of edible fungi in gut microbiota regulation.NPJ science of food · 2025Review
- Engineered probiotics: a new era in treating inflammatory bowel disease.Journal of translational medicine · 2025Review
- Characteristics of Novel Fermented Cloudy Fruit Juices Produced UsingMolecules (Basel, Switzerland) · 2025Article
- [Research progress on the relationship between gut microbiota and childhood bronchial asthma].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Review
- Microbial metabolite-driven immune reprogramming in tumor immunotherapy: mechanisms and therapeutic perspectives.Frontiers in immunology · 2025Review
- The role of short-chain fatty acid in metabolic syndrome and its complications: focusing on immunity and inflammation.Frontiers in immunology · 2025Review
- Engineering probioticApplied and environmental microbiology · 2024Article
- Recent advances in bacteria-based platforms for inflammatory bowel diseases treatment.Exploration (Beijing, China) · 2024Review
- Article
- Short-chain fatty acids: linking diet, the microbiome and immunity.Nature reviews. Immunology · 2024Review
- Minimizing endogenous cryptic plasmids to construct antibiotic-free expression systems forSynthetic and systems biotechnology · 2024Article
- Glycerol tributylate (Triacylglycerol tributanoate) promoted the liver lipid metabolism by cultivating the intestinal flora of grass carp (Ctenopharyngodon idellus).Fish physiology and biochemistry · 2023Article
- L-Fucose is involved in human-gut microbiome interactions.Applied microbiology and biotechnology · 2023Review
- The Probiotic Combination ofNutrients · 2023Article
- Advances inMaterials today. Bio · 2023Article
- Enhancing intestinal barrier efficiency: A novel metabolic diseases therapy.Frontiers in nutrition · 2023Review
- Revitalizing myocarditis treatment through gut microbiota modulation: unveiling a promising therapeutic avenue.Frontiers in cellular and infection microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Faecalibacterium prausnitzii (F. prausnitzii) is one of the most abundant bacteria in the human intestine, with its anti-inflammatory effects establishing it as a major effector in human intestinal health. However, its extreme sensitivity to oxygen makes its cultivation and physiological study difficult. F. prausnitzii produces butyric acid, which is beneficial to human gut health. Butyric acid is a short-chain fatty acid (SCFA) produced by the fermentation of carbohydrates, such as dietary fibre in the large bowel. The genes encoding butyryl-CoA dehydrogenase (BCD) and butyryl-CoA:acetate CoA transferase (BUT) in F. prausnitzii were cloned and expressed in E. coli to determine the effect of butyric acid production on intestinal health using DSS-induced colitis model mice. The results from the E. coli Nissle 1917 strain, expressing BCD, BUT, or both, showed that BCD was essential, while BUT was dispensable for producing butyric acid. The effects of different carbon sources, such as glucose, N-acetylglucosamine (NAG), N-acetylgalactosamine (NAGA), and inulin, were compared with results showing that the optimal carbon sources for butyric acid production were NAG, a major component of mucin in the human intestine, and glucose. Furthermore, the anti-inflammatory effects of butyric acid production were tested by administering these strains to DSS-induced colitis model mice. The oral administration of the E. coli Nissle 1917 strain, carrying the expression vector for BCD and BUT (EcN-BCD-BUT), was found to prevent DSS-induced damage. Introduction of the BCD expression vector into E. coli Nissle 1917 led to increased butyric acid production, which improved the strain's health-beneficial effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.